Saturday, July 11, 2026

pharma · Colorectal Cancer Metastatic

Dai, Guanghai

Dai, Guanghai drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
1
Patents
0
Intelligence · Drug Pipeline

Dai, Guanghai pipeline

Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Dai, Guanghai drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

1 compounds
  1. fruquintinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.

    Target
    Vascular endothelial growth factor receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor